



(11) **EP 1 443 925 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (48) Corrigendum issued on:
28.02.2007 Bulletin 2007/09
- (45) Date of publication and mention of the grant of the patent:
27.12.2006 Bulletin 2006/52
- (21) Application number: **02787554.1**
- (22) Date of filing: **04.11.2002**
- (51) Int Cl.:
A61K 31/4375^(2006.01) C07D 471/04^(2006.01)
A61P 11/00^(2006.01) A61P 29/00^(2006.01)
A61P 37/00^(2006.01)
- (86) International application number:
PCT/EP2002/012300
- (87) International publication number:
WO 2003/039544 (15.05.2003 Gazette 2003/20)

(54) **NAPHTHYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOSPHODIESTERASE ISOENZYME 4 (PDE4) INHIBITORS**

NAPHTHYRIDINE DERIVATE, IHRE HERSTELLUNG UND IHRE ANWENDUNG ALS PHOSPHODIESTERASE ISOENZYME 4 (PDE4) INHIBITOREN

DERIVES DE NAPHTHYRIDINE, PREPARATION ET UTILISATION EN TANT QU'INHIBITEURS DE L'ISOENZYME PHOSPHODIESTERASE 4 (PDE4)

- (84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
RO SI
- (30) Priority: **05.11.2001 GB 0126511**
30.04.2002 GB 0209882
- (43) Date of publication of application:
11.08.2004 Bulletin 2004/33
- (73) Proprietors:
• **Novartis AG**
4056 Basel (CH)
Designated Contracting States:
BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
• **Novartis Pharma GmbH**
1235 Vienna (AT)
Designated Contracting States:
AT
- (72) Inventors:
• **DENHOLM, Alastair,**
Novartis Horsham Research Ctr.
Horsham,
West Sussex RH12 5AB (GB)
• **KELLER, Thomas, H.,**
Novartis Pharmaceuticals
Horsham,
West Sussex RH12 5AB (GB)
• **MCCARTHY, Clive,**
c/o Novartis AG
4056 Basel (CH)
• **PRESS, Neil, J.,**
Novartis Horsham Research Centre
Horsham,
West Sussex RH12 5AB (GB)
• **TAYLOR, Roger, J.,**
Novartis Horsham Research Ctr.
Horsham,
West Sussex RH12 5AB (GB)
- (74) Representative: **de Weerd, Petrus G.W. et al**
Novartis International AG
Corporate Intellectual Property
4002 Basel (CH)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 443 925 B8

(56) References cited:

WO-A-98/18796

- **HERSPERGER R. ET AL.: "Pd-Catalysed Cross-Coupling Reactions for the Synthesis of 6,8-Disubstituted 1,7-Naphtyridines: A Novel Class of Potent and Selective Phosphodiesterase Type 4D Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, 2000, pages 675-682, XP002234191**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification